Live tape
Top 8, mentions 7d30,017NVDA14,564 mentions▲ +0.04ANT4,160 mentions▲ +0.06GOOGL2,936 mentions▲ +0.04SPY2,248 mentions▲ +0.05QQQ1,804 mentions▲ +0.04SPCX1,748 mentions▲ +0.08AMD1,367 mentions▲ +0.06AAPL1,190 mentions▲ +0.04

Equity · Healthcare

KRYS

NASDAQ

Krystal Biotech (KRYS)

346 USD −0.60% vs prior close Sep 10, 2026
Krystal Biotech, Inc. price graph
13 sessions
380 340 24 Aug 10 Sep

The line runs 342 USD on 24 August through 346 USD on 10 September, on a scale from 340 to 380. Days the market did not trade hold the previous close, flat.

Market cap
10.3B USD
P/E (TTM)
47.0
Revenue, year to Dec 2025
389.1M USD
EPS, diluted, year to Dec 2025
6.84 USD
52-week range
137.45 USD – 378.20 USD
Avg volume
37.5K

as of Sep 10, 2026

Have Krystal Biotech (KRYS) insiders bought or sold shares recently?

In the 90 days to 22 Nov 2026, Krystal Biotech insiders reported 2 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 24 Feb 2026, show no open-market purchase.

Form 4, 90 days to 22 Nov 2026, newest reported trade 4 Sep 2026

0buys
2sells
$17.97Mnet sold
1other filings
Have Krystal Biotech (KRYS) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
04 Sep 2026Krishnan Krish SPresident and CEOSell25,0009.0M USD
04 Sep 2026Krishnan SumaPresident, R&DSell25,0009.0M USD
Sold2 open-market sales50,000$17.97M
1 other filing in the window: a grant, exercise, tax withholding or transfer, not a trade
Have Krystal Biotech (KRYS) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
12 Nov 2026ROSSI DINO ADirectorGift3,500

Which funds hold Krystal Biotech (KRYS)?

7 of the 45 institutional funds we track reported a Krystal Biotech position for the quarter ended 30 Sep 2026 — a combined 94.8M USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Krystal Biotech (KRYS)?
FundPositionSharesValueShares q/q
Bridgewater AssociatesAdded99,92033.2M USD+83.4%
Renaissance TechnologiesHeld (±25%)63,12021.0M USD+5.8%
Citadel AdvisorsAdded44,54814.8M USD+1,534.8%
Two Sigma InvestmentsAdded29,5949.8M USD+386.4%
Fisher Asset ManagementHeld (±25%)26,9529.0M USD−2.6%
AQR Capital ManagementAdded18,7776.2M USD+34.1%
Marshall WaceNew position2,232742K USD

Have members of Congress traded Krystal Biotech (KRYS)?

The most recent congressional trade disclosed in Krystal Biotech is a purchase by Sara Jacobs (house, CA), dated 12 Dec 2022.

STOCK Act disclosures

Have members of Congress traded Krystal Biotech (KRYS)?
TradedMemberTypeAmountFiled after
12 Dec 2022Sara Jacobshouse · Democrat–CAPurchase1K USD–15K USD39 days

What has been filed or recorded for Krystal Biotech (KRYS)?

The filings we hold for Krystal Biotech, newest first: 6 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 22 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Krystal Biotech (KRYS)?
And
22 Oct 2026Fails to deliverShares failed to deliver3,350 shares1.1M USD notional · 0.011% of shares out
20 Oct 2026Fails to deliverShares failed to deliver3,151 shares1.0M USD notional · 0.011% of shares out
19 Oct 2026Fails to deliverShares failed to deliver5,519 shares1.7M USD notional · 0.019% of shares out
16 Oct 2026Fails to deliverShares failed to deliver769 shares254K USD notional · 0.003% of shares out
14 Oct 2026Fails to deliverShares failed to deliver562 shares180K USD notional · 0.002% of shares out
09 Oct 2026Fails to deliverShares failed to deliver115 shares38K USD notional · <0.001% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS 2.05 USDRevenue $127M
30 Sep 2026FinancialsTotal assets1.6B USDat period end
30 Sep 2026FinancialsTotal equity1.4B USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS 1.79 USDRevenue $119M
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS 1.83 USDRevenue $116M
31 Dec 2025Annual reportFY 2025 reportedEPS 6.84 USDRevenue $389M
31 Dec 2025FinancialsRevenue389.1M USDfiscal year
31 Dec 2025FinancialsNet income204.8M USDfiscal year
31 Dec 2025FinancialsDiluted EPS6.84 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS 2.66 USDRevenue $98M
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS 1.29 USDRevenue $96M
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS 1.20 USDRevenue $88M
31 Dec 2024Annual reportFY 2024 reportedEPS 3.00 USDRevenue $291M

What do people ask about Krystal Biotech (KRYS)?

From live data
What did Krystal Biotech shares close at?346.00

Krystal Biotech closed at 346.00 USD on 10 Sep 2026, down 0.60% on the close before. That is the end-of-day price from Finazon, not a live quote.

What is Krystal Biotech’s market cap?10.3B

Krystal Biotech is worth 10.3B USD by market value as of 10 Sep 2026, which is the share price times the shares on issue from its SEC filings.

What is Krystal Biotech’s P/E ratio?47.0

Krystal Biotech has a price-to-earnings ratio of 47.0, as of 10 Sep 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.

What is Krystal Biotech’s revenue?389.1M

Krystal Biotech reported revenue of 389.1M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Krystal Biotech insiders bought or sold shares recently?2 sales

In the 90 days to 22 Nov 2026, Krystal Biotech insiders reported 2 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 24 Feb 2026, show no open-market purchase. A further 1 filing was a grant, award, gift or exercise rather than an open-market trade. See Insiders

Which funds own Krystal Biotech?7 of 45

7 of the 45 funds we track reported a Krystal Biotech position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Bridgewater Associates, Renaissance Technologies and Citadel Advisors. See Funds

Have members of Congress traded Krystal Biotech?1 trade

Yes. 1 trade in Krystal Biotech appears in the congressional disclosures we hold: a purchase by Sara Jacobs (House, CA) dated 12 Dec 2022, filed 20 Jan 2023. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress

When did Krystal Biotech last report earnings?2.05

Krystal Biotech last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 2.05 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close), most closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. Wikimedia CommonsPortraits via Wikimedia Commons. Sara Jacobs: Kristie Baxter, Public domain.
  6. House disclosuresU.S. House of Representatives financial disclosures
  7. SECSEC fails-to-deliver (CNS) data
  8. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  9. SEC EDGARreported earnings figures and scheduled report dates
  10. SEC EDGARValuation computed from SEC EDGAR filings
  11. SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words